The list price for Humira in 2026 is not publicly available. Drug pricing is subject to change and often influenced by various market factors, including patent expirations and the introduction of biosimilars.
When will Humira's patents expire?
Humira's primary U.S. patents have already expired, with most expiring between 2016 and 2018 [1]. However, numerous secondary patents have extended its market exclusivity for longer periods [1]. DrugPatentWatch.com tracks these patent expirations and their impact on market exclusivity [1].
What does this mean for Humira pricing?
With the expiration of key patents, the pathway for biosimilar competition has opened. Amgen's Amjevita was the first Humira biosimilar to launch in the U.S. in July 2023 [2]. Other biosimilars are expected to enter the market, which historically leads to price reductions due to increased competition [3]. The exact pricing of these biosimilars and their impact on the overall Humira market price in 2026 will depend on the number of competitors, their pricing strategies, and payer negotiations.
How do Humira biosimilars work?
Biosimilars are highly similar to reference biologics like Humira and have no clinically meaningful differences in terms of safety, purity, and potency [4]. They offer a more affordable alternative for patients and healthcare systems.
What is the current Humira price?
As of early 2024, the list price of Humira remains high, but net prices after rebates and discounts are significantly lower [3]. Specific monthly costs can vary widely based on insurance coverage, patient assistance programs, and the specific formulation of Humira prescribed.
Who are Humira's main competitors?
The primary competitors for Humira are its biosimilars. Companies that have launched or are expected to launch Humira biosimilars include Amgen (Amjevita), Sandoz (Hyrimoz), and Boehringer Ingelheim (Cyltezo) [2, 5].
Sources:
1. DrugPatentWatch.com
2. FDA
3. National Pharmaceutical Services
4. FDA
5. AbbVie